← all works
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Head and Neck Cancer Studies
- Field
- Medicine
- Canadian institutions
- Centre Hospitalier de l’Université de Montréal
- Funders
- Merck Sharp and DohmeNational Institute for Health and Care Research
- Keywords
- CetuximabMedicineDocetaxelPembrolizumabOncologyOpen labelInternal medicineHead and neckMethotrexateHead and neck squamous-cell carcinomaHead and neck cancerPhases of clinical researchChemotherapyRandomized controlled trialSurgeryRadiation therapyCancerImmunotherapy
- Has abstract in OpenAlex
- no